Hosted on MSN1mon
Maze Therapeutics IPO opens trading modestly higher
Investing.com -- Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares starting to trade at $16.12. The company priced ...
Hosted on MSN2mon
Kidney disease drug developer Maze files for $100M IPO
Maze Therapeutics (MAZE), which is developing treatments for chronic kidney disease, has filed to raise $100M through an initial public offering. While the company didn't disclose terms in its SEC ...